← Oncology Approval Tracker

FDA DECISION ·

Tecentriq

atezolizumab · Genentech

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adjuvant treatment after resection and platinum chemotherapy for stage II to IIIA non-small cell lung cancer with PD-L1 on at least 1% of tumor cells by an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

The decision uses postoperative stage and a tumor-cell PD-L1 threshold to select an adjuvant population.

What research teams should watch

Record pathologic stage, surgery and chemotherapy dates, and the assay-specific tumor-cell score.

PRIMARY RECORDS

Sources